Nxera Pharma Co., Ltd.
Achieved the 4th milestone in the AbbVie collaboration for drug discovery and holds up to $1.2 billion in additional milestone rights
Achieved the 4th milestone in the AbbVie drug discovery collaboration and received $10 million. In 2026, the 2nd milestone will be reached, and rights to up to $1.2 billion in additional milestones and tiered royalties remain. The 2026 fiscal year outlook already factors in this impact.
Key Figures
- 10 million USD: milestone receipts
- Up to 1.2 billion USD: milestone cap
- 2026: 2nd milestone achieved
AI要約
News Highlights
Nexera Pharma has achieved the 4th milestone in its neural disorder drug discovery collaboration with AbbVie, receiving $10 million. The 2nd milestone is expected in 2026, and the company retains rights to up to $1.2 billion in milestones and royalties upon further option exercises and achievement of development and commercialization goals. The impact is already reflected in the 2026 earnings guidance.
Outlook
The collaboration aims to generate new drugs targeting GPCR using the NxWave™ platform, with multiple pipelines progressing in 2026. Most milestones are recognized in 2026, and revenue realization may continue beyond 2027.
Nexera Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
